Online inquiry

IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1838MR)

This product GTTS-WQ1838MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1838MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8046MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ8895MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ7791MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ14680MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ15146MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SYNT-001
GTTS-WQ6207MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CR4098
GTTS-WQ2597MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ1744MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW